SEC Form 4 · accession 0001209191-18-057373
bluebird bio, Inc. · BLUE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Davidson
Officer — Chief Medical Officer
Period of report
Nov 2, 2018
Accepted (ET)
Nov 6, 2018 · 4:15 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001293971
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 2, 2018 | M | 5,000 | $5.5004 | A | 29,905 | D | |
| Common Stock | Nov 2, 2018 | S | 92 | $128.30 | D | 29,813 | D | |
| Common StockF2 | Nov 2, 2018 | S | 405 | $130.4177 | D | 29,408 | D | |
| Common StockF3 | Nov 2, 2018 | S | 501 | $131.3727 | D | 28,907 | D | |
| Common StockF4 | Nov 2, 2018 | S | 600 | $133.083 | D | 28,307 | D | |
| Common StockF5 | Nov 2, 2018 | S | 1,702 | $134.115 | D | 26,605 | D | |
| Common StockF6 | Nov 2, 2018 | S | 1,700 | $135.0954 | D | 24,905 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F7 | $5.5004 | Nov 2, 2018 | M | 5,000 | D | — | Jan 16, 2023 | Common Stock | 5,000 | 26,951 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2017.
- F2The range in prices for the transaction reported on this line was $130.00 to $130.58. The average weighted price was $130.4177. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3The range in prices for the transaction reported on this line was $131.1225 to $131.70. The average weighted price was $131.3727. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4The range in prices for the transaction reported on this line was $132.65 to $133.56. The average weighted price was $133.083. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F5The range in prices for the transaction reported on this line was $133.66 to $134.52. The average weighted price was $134.115. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F6The range in prices for the transaction reported on this line was $134.94 to $135.78. The average weighted price was $135.0954. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F7This option to purchase shares of our common stock was granted on January 16, 2013 with performance-based vesting criteria that were met as of January 1, 2013. The shares underlying these options vested as follows: 25% vested on January 1, 2014, with the remainder of the shares vesting in equal monthly installments over the following three years.